sofpironium; ACTUAT sofpironium (Sofdra)

Indications

• treatment of primary axillary hyperhidrosis in adults & pediatric patients >=9 years

Contraindications

• conditions exacerbated by anticholinergic agents
  • glaucoma, paralytic ileus, severe ulcerative colitis, toxic megacolon, myasthenia gravis, Sjogren's syndrome

Dosage

• 1 pump underarm daily

Topical gel: 12.45% of sofpironium

Pharmacokinetics

• metabolized by nonenzymatic hydrolysis, CYP2D6 & CYP3A4 with glycine conjugation
• does not affect QTc

Adverse effects

• anticholinergic effects
  • urinary retention
  • blurred vision
  • application site erythema,
  • mydriasis
  • xerostomia (dry mouth)

• drug adverse effects of parasympatholytics

Drug interactions

• anticholinergic agents
• strong inhibitors of CYP2D6 (prolongs 1/2 life of sofpironium)

• drug interaction(s) of parasympatholytic with parasympathomimetic

Mechanism of action

• competitive inhibitor of muscarinic receptors associated with sweat glands

More general terms

• parasympatholytic (anticholinergic, antimuscarinic agent)
• dermatologic agent
• topical agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=86301317
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=86301316